Investee Company News

July 16, 2018 Immunocore Management Change June 4, 2018 New IMCgp100-102 Data Show Durable Response and Robust Overall Survival Rate in Patients with Metastatic Uveal Melanoma May 29, 2018 Melinta Therapeutics Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock May 24, 2018 Melinta Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference May 23, 2018 Melinta Therapeutics Announces Pricing of Public Offering of Common Stock May 22, 2018 Immunocore to Present New Data from IMCgp100-102 Trial in Metastatic Uveal Melanoma at 2018 ASCO Annual Meeting May 21, 2018 Melinta Therapeutics Announces Proposed Offering of Common Stock May 17, 2018 SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment May 15, 2018 Novan Provides Update on SB414 Inflammatory Skin Disease Development Program May 8, 2018 Melinta Therapeutics Reports First Quarter 2018 Financial Results May 7, 2018 Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria May 1, 2018 Melinta Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018 April 26, 2018 Poseida Therapeutics Presents Clinical Manufacturing Method for Durable, Persistent CAR-T Stem Cell Memory Therapies at World Orphan Drug Congress USA April 23, 2018 Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations April 23, 2018 Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018 April 17, 2018 Altan Pharma Announces the Grant of Two Patents by the USPTO April 17, 2018 Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma April 16, 2018 Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018 April 12, 2018 Novan Advances Organization and Strengthens Leadership Team April 3, 2018 Poseida Raises $30.5 Million in Series B Financing March 26, 2018 Poseida to Present P-BCMA-101 Phase 1 Data at the American Association for Cancer Research (AACR) Annual Meeting 2018 March 13, 2018 Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results March 8, 2018 Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe March 2, 2018 Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care Conference February 28, 2018 Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer February 28, 2018 Melinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018 February 28, 2018 Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ in Patients with cUTI February 21, 2018 Dr. Eugene Sun Appointed to Novan Board of Directors February 20, 2018 Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina February 14, 2018 Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies